Baseline Laboratory Testing Before Hormone Replacement Therapy in Women
For standard menopausal hormone replacement therapy, obtain a pregnancy test (if applicable), baseline mammography, and lipid profile—routine hormone level measurements are not necessary or beneficial for initiating HRT in typical menopausal women 1, 2.
Essential Baseline Tests for Standard Menopausal HRT
Mandatory Testing
- Pregnancy test (β-hCG): Required in women with amenorrhea who could potentially be pregnant 3
- Mammography: Essential for excluding breast malignancy before initiating therapy 4
- Lipid profile: Assess cardiovascular risk factors 3, 5
Not Routinely Required
Hormone levels (FSH, estradiol) should NOT be routinely measured before starting HRT in typical menopausal women, as diagnosis is clinical and hormone levels do not guide treatment decisions 6, 1. The correlation between symptoms and testosterone levels has not been established, making routine measurement unhelpful 6.
Context-Specific Laboratory Panels
For Premature Ovarian Insufficiency (POI) or Functional Hypothalamic Amenorrhea (FHA)
When HRT is indicated for women under age 40 or with premature menopause, obtain:
Endocrine panel 3:
- TSH and free T4
- Prolactin
- LH and FSH
- Estradiol (E2)
- Anti-Müllerian hormone (AMH)
Additional testing if clinically indicated 3:
- Total testosterone and DHEA-S (if clinical hyperandrogenism present)
- 8 AM 17-hydroxyprogesterone (if suspecting late-onset congenital adrenal hyperplasia)
- Complete blood count
- Comprehensive metabolic panel (electrolytes, glucose, BUN, creatinine, liver function)
- ESR/CRP (if chronic illness suspected)
Bone health assessment 3:
- Baseline bone mineral density (BMD) by DXA for any woman with ≥6 months amenorrhea, or earlier if severe nutritional deficiency or skeletal fragility suspected
For Women with Hypopituitarism
If replacing gonadal hormones in hypopituitarism, measuring serum estradiol levels is not beneficial during follow-up, as some estrogens are not detected by assays 7. Focus instead on symptom evaluation and monitoring for side effects.
Risk Stratification Testing
Cardiovascular Assessment
- Blood pressure measurement 7, 5
- Fasting glucose or HbA1c (if diabetes risk factors present) 3
- Consider inflammatory markers (CRP) in high-risk patients 5
Thrombosis Risk
No routine thrombophilia screening is needed unless personal or family history suggests coagulation abnormalities 8. If VTE history or thrombophilia present, refer to hematology before initiating HRT 9.
Endometrial Assessment
- Pelvic examination: Evaluate for abnormal bleeding or masses 3
- Transvaginal ultrasound: Not routinely required pre-treatment but consider if abnormal bleeding present 4
- Endometrial biopsy: Only if clinically indicated by abnormal bleeding, not routine 10
Special Populations
Women with BRCA Mutations or Post-RRSO
- Standard pre-HRT workup as above
- No additional hormone testing required 8
- Consider baseline BMD 1-2 years post-surgery if additional osteoporosis risk factors 8
Androgen Therapy Consideration
If considering testosterone therapy (only indicated for postmenopausal HSDD):
- Baseline total testosterone level before initiation 6, 11
- Repeat at 3-6 weeks after starting 6, 11
- Monitor every 6 months thereafter 6
Common Pitfalls to Avoid
Do not delay HRT initiation waiting for FSH/estradiol results in clearly menopausal women—these tests add no clinical value 6, 1
Do not routinely screen thyroid function unless symptoms suggest thyroid disease 3
Do not perform routine endometrial sampling before HRT in asymptomatic women 10
Do not measure hormone levels to "dose" standard HRT—clinical response guides therapy, not serum levels 7, 1
Avoid compounded "bioidentical" preparations that lack standardized dosing and safety data 11
The evidence consistently shows that clinical assessment trumps laboratory testing for most women initiating standard menopausal HRT. Reserve extensive hormonal workups for younger women with premature ovarian insufficiency, suspected secondary causes of amenorrhea, or when diagnosis is uncertain 3.